Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794
- Research Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Research Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women ≥ 18 years old
- Pathologically documented, definitively diagnosed AML that has failed standard treatments or for which no standard therapy is available or the subject refuses standard therapy
- Must consent to undergo bone marrow biopsies per schedule of assessments
Exclusion Criteria:
- White blood cell greater than 20,000 uL
- History of or active central nervous system leukemia
- Prior allogeneic bone marrow transplant
- Subject will not be available for protocol-required study visits or procedures
Other Inclusion/ Exclusion Criteria may apply to qualify for enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1- Dose Escalation
The dose escalation will be conducted in 2 parts.
Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts.
The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
|
AMG 900 is a small molecule aurora kinase inhibitor.
AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
|
|
Experimental: Arm 2- Dose Expansion
The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 20 subjects with acute myelogenous leukemia.
|
AMG 900 is a small molecule aurora kinases inhibitor.
The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Subject incidence of adverse events
Time Frame: 1 year
|
1 year
|
|
Subject incidence of dose limiting toxicities (DLTs)
Time Frame: 1 year
|
1 year
|
|
Maximum observed concentration of AMG 900
Time Frame: 1 year
|
1 year
|
|
Time to maximum observed concentration of AMG 900
Time Frame: 1 year
|
1 year
|
|
Area under the plasma concentration-time curve (AUC) of AMG 900
Time Frame: 1 year
|
1 year
|
|
Half life of AMG 900
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective response as per Cheson Response Criteria
Time Frame: 1 year
|
1 year
|
|
Change in the number of p-Histone H3 positive cells from baseline
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20101351
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.